AI assistant
Sending…
REGENERON PHARMACEUTICALS, INC. — Director's Dealing 2017
Oct 3, 2017
29977_dirs_2017-10-03_f0305fe6-32e5-4d11-aac0-f35734cd1d25.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: REGENERON PHARMACEUTICALS INC (REGN)
CIK: 0000872589
Period of Report: 2017-09-29
Reporting Person: BAKER CHARLES A (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2017-09-29 | Common Stock | M | 2000 | $18.61 | Acquired | 11000 | Direct |
| 2017-09-29 | Common Stock | S | 2000 | $450.0 | Disposed | 9000 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2017-09-29 | Non-Qualified Stock Option (right to buy) | $18.61 | M | 2000 | Disposed | 2019-01-02 | Common Stock (2000) | Direct |
Footnotes
F1: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).
F2: The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant.
More from REGENERON PHARMACEUTICALS, INC.
Regulatory Filings
2026
May 8
Major Shareholding Notification
2026
Apr 30
Interim / Quarterly Report
2026
Apr 29
Regulatory Filings
2026
Apr 29
Annual Report
2026
Apr 24
Proxy Solicitation & Information Statement
2026
Apr 24
Proxy Solicitation & Information Statement
2026
Apr 24
Regulatory Filings
2026
Apr 8
Major Shareholding Notification
2026
Mar 27
Director's Dealing
2026
Mar 3